Your browser is no longer supported. Please, upgrade your browser.
ADMS Adamas Pharmaceuticals, Inc. monthly Stock Chart
ADMS [NASD]
Adamas Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.32 Insider Own1.90% Shs Outstand28.03M Perf Week-4.62%
Market Cap72.09M Forward P/E- EPS next Y-1.30 Insider Trans0.00% Shs Float27.41M Perf Month-8.82%
Income-92.20M PEG- EPS next Q-0.61 Inst Own79.80% Short Float2.61% Perf Quarter-22.01%
Sales57.50M P/S1.25 EPS this Y22.00% Inst Trans4.06% Short Ratio1.64 Perf Half Y-51.75%
Book/sh-0.57 P/B- EPS next Y40.60% ROA-53.70% Target Price- Perf Year-58.74%
Cash/sh3.96 P/C0.63 EPS next 5Y46.30% ROE-806.50% 52W Range1.90 - 7.78 Perf YTD-34.56%
Dividend- P/FCF- EPS past 5Y-52.90% ROI-72.70% 52W High-68.12% Beta1.79
Dividend %- Quick Ratio5.40 Sales past 5Y-0.40% Gross Margin95.40% 52W Low30.53% ATR0.14
Employees136 Current Ratio5.60 Sales Q/Q23.90% Oper. Margin- RSI (14)43.42 Volatility4.38% 5.29%
OptionableYes Debt/Eq- EPS Q/Q45.00% Profit Margin- Rel Volume0.39 Prev Close2.56
ShortableYes LT Debt/Eq- EarningsAug 06 AMC Payout- Avg Volume437.44K Price2.48
Recom2.20 SMA20-4.80% SMA50-8.38% SMA200-36.77% Volume172,593 Change-3.12%
Dec-18-19Reiterated H.C. Wainwright Buy $30 → $10
Sep-30-19Downgrade BofA/Merrill Neutral → Underperform $9 → $5
Sep-09-19Initiated Cantor Fitzgerald Neutral $8
Mar-05-19Downgrade Mizuho Neutral → Underperform $11 → $5
Nov-05-18Downgrade Mizuho Buy → Neutral
Oct-05-18Downgrade BofA/Merrill Buy → Neutral
Jul-16-18Initiated H.C. Wainwright Buy $45
Apr-04-18Initiated Leerink Partners Outperform $31
Mar-27-18Initiated BofA/Merrill Buy $39
Nov-29-17Initiated Northland Capital Outperform $70
Nov-08-17Reiterated Noble Financial Buy $33 → $48
Oct-30-17Initiated Evercore ISI Outperform $85
Sep-29-17Resumed Noble Financial Buy $33
Sep-19-17Reiterated Mizuho Buy $26 → $48
Aug-25-17Reiterated JMP Securities Mkt Outperform $29 → $33
Sep-08-16Reiterated Mizuho Buy $22 → $26
Jun-17-16Initiated Noble Financial Buy $25
Jun-16-16Upgrade Mizuho Neutral → Buy $22
May-12-16Reiterated Mizuho Neutral $17 → $16
Apr-28-16Reiterated Mizuho Neutral $14 → $17
Jul-30-20 12:33PM  
Jul-23-20 04:02PM  
Jul-15-20 08:00AM  
Jul-10-20 04:05PM  
Jun-18-20 08:34AM  
Jun-17-20 04:01PM  
Jun-05-20 07:34AM  
Jun-04-20 04:30PM  
Jun-03-20 04:01PM  
May-20-20 10:04PM  
May-13-20 09:15AM  
May-08-20 06:46PM  
May-07-20 04:03PM  
Apr-30-20 12:34PM  
Apr-28-20 12:00PM  
Apr-27-20 04:03PM  
Apr-10-20 04:06PM  
Mar-23-20 03:15PM  
Mar-20-20 10:44AM  
Mar-19-20 04:46PM  
Mar-10-20 02:26PM  
Mar-06-20 04:39PM  
Feb-28-20 06:26AM  
Feb-25-20 05:35PM  
04:03PM  
Feb-24-20 09:02AM  
Feb-20-20 04:01PM  
Feb-19-20 04:02PM  
Feb-13-20 09:00AM  
Feb-12-20 09:18AM  
Feb-11-20 04:15PM  
Feb-10-20 10:50AM  
10:00AM  
09:57AM  
Feb-09-20 10:25AM  
Feb-08-20 10:30AM  
Feb-07-20 01:30PM  
10:00AM  
Feb-06-20 05:40PM  
01:30PM  
Feb-05-20 06:00PM  
03:15PM  
01:40PM  
11:26AM  
10:52AM  
09:56AM  
Feb-04-20 08:40PM  
08:05PM  
01:41PM  
12:30PM  
12:00PM  
11:12AM  
10:12AM  
Feb-03-20 03:45PM  
01:45PM  
01:00PM  
10:45AM  
10:11AM  
Feb-01-20 02:17PM  
02:00PM  
Jan-31-20 04:35PM  
02:22PM  
01:55PM  
01:37PM  
01:15PM  
11:16AM  
10:20AM  
09:57AM  
Jan-30-20 01:10PM  
Jan-29-20 04:40PM  
01:30PM  
01:19PM  
11:30AM  
09:00AM  
Jan-28-20 08:55PM  
03:10PM  
12:30PM  
12:13PM  
11:47AM  
10:00AM  
Jan-27-20 06:55PM  
05:06PM  
01:40PM  
11:15AM  
11:00AM  
10:45AM  
09:35AM  
Jan-26-20 07:55AM  
Jan-24-20 05:15PM  
03:12PM  
10:25AM  
10:00AM  
Jan-23-20 05:44PM  
11:35AM  
11:00AM  
Jan-22-20 02:50PM  
02:00PM  
01:19PM  
10:50AM  
09:07AM  
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Prentiss Christopher BChief Financial OfficerJan 21Sale5.921,2697,51270,940Jan 23 05:33 PM
MERRIWEATHER ALFRED GChief Financial OfficerSep 20Sale6.911,58410,94548,019Sep 23 04:19 PM
MAHONEY DAVID LDirectorSep 17Option Exercise1.7633,33258,49857,153Sep 18 04:38 PM